A Uveitis Eye Drug Candidate Clears a Full Year in Phase III
A Uveitis Eye Drug Candidate Clears a Full Year in Phase III
Roche has reported new one-year Phase III data for vamikibart, an investigational antibody being developed for uveitic macular edema (UME), a vision-threatening complication of uveitis. Results from the MEERKAT and SANDCAT studies showed that improvements in vision and reductions in retinal swelling were maintained through 52 weeks.
Food and Drug Administration has accepted its Biologics License Application (BLA) for vamikibart, moving the candidate further along the regulatory pathway.
Vamikibart Targets Inflammation Behind Uveitic Macular Edema
Vamikibart is an investigational monoclonal antibody designed for intravitreal administration. It targets interleukin-6 (IL-6), an inflammatory cytokine involved in the disease pathway associated with UME.
UME occurs when inflammation linked to uveitis causes fluid to accumulate in the macula, the central region of the retina responsible for detailed vision. The condition is considered the leading cause of moderate-to-severe vision loss among people with uveitis.
The candidate is being developed as a non-steroid targeted treatment. This is significant because corticosteroids remain an important treatment approach for UME but can cause complications such as increased intraocular pressure, glaucoma and cataracts with longer-term use.
MEERKAT and SANDCAT Reach the 52-Week Mark
The new data come from two identical Phase III studies: MEERKAT (NCT05642312) and SANDCAT (NCT05642325).
Both were global, randomized, double-masked, sham-controlled studies involving adults with UME. Patients received either 0.25 mg or 1 mg of vamikibart or sham injections during the initial treatment period, followed by as-needed treatment through Week 52.
The primary endpoint was the proportion of patients achieving an improvement of at least 15 letters in best-corrected visual acuity (BCVA) at Week 16. The studies also evaluated changes in BCVA and central subfield thickness (CST), a measure of retinal swelling.
Vision and Retinal Thickness Improvements Continued
At Week 52, a numerically higher proportion of vamikibart-treated patients achieved the specified vision improvement compared with sham treatment in both studies.
Roche also reported sustained improvements in average BCVA and reductions in CST. These findings indicate that the improvements observed during the earlier treatment period were generally maintained through one year rather than disappearing after the initial response.
The results are particularly relevant for UME because persistent retinal swelling can damage vision and interfere with activities such as reading and driving.
Treatment Burden Remained Relatively Low
The 52-week analysis also provided information about retreatment requirements.
According to Roche, approximately two-thirds of eligible patients did not require retreatment after the initial 16-week treatment period. Among patients who did require additional treatment, the majority needed only one further injection during the remainder of the study period.
If confirmed in regulatory review and future clinical use, this treatment pattern could be important because reducing injection frequency may lower the treatment burden associated with chronic retinal disease.
Safety Profile Remained Favourable
Roche reported that vamikibart remained well tolerated through the one-year analysis. Treatment-related ocular adverse events and intraocular inflammation events were reported at low rates, according to the company.
The Phase III studies also monitored safety events including intraocular inflammation and retinal occlusive vasculitis. Longer-term safety remains an important consideration because vamikibart is intended for repeated intravitreal administration.
As with the efficacy findings, these results represent clinical-trial data and do not establish that the candidate will ultimately be approved or provide the same outcomes for all patients.
FDA Review Moves Forward
Alongside the 52-week results, Roche announced that the FDA has accepted its BLA for vamikibart for UME. The agency is expected to make an approval decision by July 2027. Regulatory submissions have also been accepted in the European Union, China and Japan.
If approved, Roche says vamikibart could become the first targeted non-steroid treatment specifically developed for UME. The company is therefore positioning the candidate as a potential new treatment option for patients who face the limitations and risks associated with long-term steroid therapy.
FDA filing acceptance, however, is not an approval. The application must still undergo regulatory review of the complete clinical, manufacturing and safety package.
A Potential Shift in Uveitis Treatment
The one-year Phase III findings strengthen the development case for vamikibart by showing that both visual and anatomical improvements can persist through 52 weeks.
The results also highlight the potential of targeting specific inflammatory pathways rather than relying exclusively on broad immunosuppression or corticosteroids. Whether this translates into a new standard of care will depend on the final regulatory decisions and the complete benefit-risk assessment.
For Roche, the data represent an important milestone in its ophthalmology pipeline and move vamikibart closer to a potential commercial launch in UME.
Sources:
Stearyl Alcohol
Found this useful?
